2023 European Liver Association: Aligos' Five Innovative hepatitis B Drugs Development Core Content and Prospects
AD |
AligosTherapeutics in the clinical phase brought a total of five new research advances in innovative hepatitis B drugs at the 2023 European Liver Annual Conference (EASL2023), including two candidate drugs in the phase I clinical development phase, and progress in compounds in the pre clinical research phase. The following are the core contents of these 5 research developments and comments during the Aligos European Liver Conference
AligosTherapeutics in the clinical phase brought a total of five new research advances in innovative hepatitis B drugs at the 2023 European Liver Annual Conference (EASL2023), including two candidate drugs in the phase I clinical development phase, and progress in compounds in the pre clinical research phase. The following are the core contents of these 5 research developments and comments during the Aligos European Liver Conference.
1. A research progress released during the current European Liver Congress, which was led by Professor Hou Jinlin of China, is a kind of shell assembly regulator ALG-000184. It has been used together with Entecavir (ETV) for 28 weeks, with good tolerance. In untreated hepatitis B e antigen positive patients, the level of hepatitis B B surface antigen (HBsAg) has significantly decreased.
2. The safety, pharmacokinetics (PK) and antiviral activity of a single incremental dose of ALG-125755 (a GalNAc binding small interfering RNA) in patients with chronic hepatitis B. This study was led by AlinaJucov, M.D.
This study concluded that a siRNA aimed at reducing HBsAg (HBsAg) in patients with chronic hepatitis B (CHB), through a single subcutaneous injection of 50mg and 120mg ALG-125755, led to a dose-dependent reduction of HBsAg levels within 90 days. Importantly, the safety and PK characteristics of these dose levels also support further evaluation of higher dose levels.
3. The pharmacodynamic persistence of a GalNAc bound siRNAALG-125755 is associated with total siRNA and RNA inducible complex (RISC) binding siRNA in mouse liver. This study was led by Professor KusumGupta.
This study concludes that in AAV-HBV mice, ALG-125755 has been shown to bind to argonaute-2 (AGO-2), confirming its mechanism of action consistent with siRNA. In addition, the pharmacological response of HBsAg reduction and persistence is associated with total siRNA and RISC binding siRNA in mouse liver.
4. The preclinical pharmacokinetics, pharmacodynamics and efficacy relationship of the liver targeting PD-L1 small molecule inhibitor ALG-093702 in different in vivo models, which was mainly taught by Dr. Tongfei Wu. Summary: ALG-093702 is a liver targeted PD-L1 small molecule inhibitor that exhibits similar efficacy in vitro to the PD-L1 antibody drug Durvalumab, as well as in vivo PD-L1 target occupancy and tumor growth inhibition. Preclinical pharmacokinetics, pharmacodynamics, and efficacy data provide guidance for effective human dose prediction and medication strategies in clinical studies of oral liver targeted PD-L1 small molecule inhibitors.
5. A potent human PD-L1siRNA leads to a significant reduction in AAV-HBV infected liver cells in human PD-1/PD-L1 knockout mice through the immune activation pathway, led by Dr. Jin Hong. Conclusion: ALG-072571 is a liver targeted PD-L1 siRNA therapy. In human PD-1/PD-L1 double knockout mice, the number of hepatocytes infected by AAV hepatitis B virus (HBV) was significantly reduced through immune activation. Therefore, ALG-072571 may lead to the restoration of immune response against HBV, thereby clearing HBV infection.
Dr. Lawrence Blatt, Chairman and CEO of Aligos, commented that we are pleased to present new clinical development data for our CHB candidate drug portfolio on EASL. These data highlight the progress we have made in promoting new Targeted therapy for a variety of liver diseases. We look forward to showcasing more data in our pipeline later this year.
Conclusion of Xiaofan Health: there are mainly three highlights in the research progress of innovative hepatitis B drugs brought by Aligos at this European Liver Congress. First, the Phase 1b clinical trial of oral coating assembly regulator (CAM-E) ALG-000184 is being evaluated, bringing promising research data; Second, the results of the ongoing phase I study to evaluate the single incremental dose of ALG-125755 (a GalNAc binding small interfering RNA) in chronic hepatitis B B virus suppression subjects; Thirdly, preclinical research on new compounds such as ALG-093702 and ALG-072571 is also being promoted.
Disclaimer: The content of this article is sourced from the internet. The copyright of the text, images, and other materials belongs to the original author. The platform reprints the materials for the purpose of conveying more information. The content of the article is for reference and learning only, and should not be used for commercial purposes. If it infringes on your legitimate rights and interests, please contact us promptly and we will handle it as soon as possible! We respect copyright and are committed to protecting it. Thank you for sharing.(Email:[email protected])
Mobile advertising space rental |
Tag: 2023 European Liver Association Aligos Five Innovative hepatitis Drugs
At the press conference for Shen16 astronauts, netizens were puzzled by one action. Why is the Guihai Tide not suitable for military etiquette?
NextThe 3rd China (Chongqing) Graphene Industry Development Forum was held
Guess you like
-
Apple Phones Banned: Why Has the Once-Shining Star Fallen From Grace?Detail
2024-10-01 12:19:49 1
-
AI Audio Incident: Hefei Police Unravel the Truth Behind Online Rumors, A Clash of Technology and JusticeDetail
2024-09-30 22:45:17 1
-
Yadea Guaneng E8: The "Rolls Royce" of Electric Vehicles, A Perfect Blend of Performance and IntelligenceDetail
2024-09-30 22:05:41 1
-
The Chaos of Live Streaming E-commerce: Deep Reflections Triggered by the San Zhi Yang False Advertising IncidentDetail
2024-09-30 19:43:26 1
-
New E-commerce Development Trends: Regulation and Empowerment, Boosting High-Quality Development of the Digital EconomyDetail
2024-09-29 18:03:14 1
- Detail
- Detail
-
Maoyan Entertainment Unveils "Shenbi Malia": AI-Powered Screenplay Creation with One-Click Dynamic Storyboard GenerationDetail
2024-09-27 15:52:43 1
-
Huawei Cloud and CAICT Jointly Released Two Value Reports to Empower City Digital Transformation and UpgradingDetail
2024-09-27 15:29:32 1
-
Huawei MateXT: Scalpers Caught in the Crossfire, High Prices Unrelenting, Can Production Ramp-Up Offer Relief?Detail
2024-09-27 14:40:15 11
-
10G-PON Leads Digital Transformation: 2024 International Information and Communication Exhibition Focuses on Innovative DevelopmentDetail
2024-09-27 14:00:08 1
-
The Light of Science Illuminates Dreams: The Path of Science Popularization at the Shandong Science and Technology MuseumDetail
2024-09-27 11:59:09 11
-
The Huawei Chip Dispute: A Balancing Act Between Independent Innovation and Open CollaborationDetail
2024-09-27 09:34:01 11
-
"Playing it Safe": Li Pao'er's Exit from Sanzhiyang, the Dilemma of "Siege" in Internet Celebrity EconomyDetail
2024-09-27 09:31:55 1
- Detail
-
From "Catching Up" to "Surpassing": The "Golden Age" of China's Precision Instrument DevelopmentDetail
2024-09-25 14:16:48 1
-
Huawei's "Closedness" and "Science": A Debate About the Direction of Technological DevelopmentDetail
2024-09-25 13:43:01 11
- Detail
- Detail
-
2024 National Day (Golden Week) Travel Guide: Amap Predicts Congested Roads, New V15 Version Helps You Say "ByeBye" to TroublesDetail
2024-09-24 14:38:15 11